BLOG

First Person Treated in Amolyt Pharma’s AZP-3601 Trial for Hypoparathyroidism

Amolyt Pharma, formerly Alizé Pharma 3, had announced earlier this year its plans to start a clinical trial of AZP-3601 by the end of 2020.